The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases
<p dir="ltr"><strong>Introduction: </strong></p><p dir="ltr"><strong></strong>PD-1 is programmed death receptor 1 belonging to the CD28 family of receptors. Immune cells have this receptor on their surface. PD-L1 allows cancer cells to av...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2020-04-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/29711 |
| _version_ | 1818911533580681216 |
|---|---|
| author | Dominika Katarzyna Madras Agata Agnieszka Rocka Klaudia Daria Szumna Patryk Piotr Jasielski Faustyna Piędel |
| author_facet | Dominika Katarzyna Madras Agata Agnieszka Rocka Klaudia Daria Szumna Patryk Piotr Jasielski Faustyna Piędel |
| author_sort | Dominika Katarzyna Madras |
| collection | DOAJ |
| description | <p dir="ltr"><strong>Introduction: </strong></p><p dir="ltr"><strong></strong>PD-1 is programmed death receptor 1 belonging to the CD28 family of receptors. Immune cells have this receptor on their surface. PD-L1 allows cancer cells to avoid the host's response. Connection to the PD-1 receptor leads to the death of the immune cell.</p><p dir="ltr"><span><strong>Objective:</strong> </span></p><p dir="ltr">The use of PD-1 receptors in the treatment of oncological, autoimmune and infectious diseases.</p><p dir="ltr"><span><strong>Abbreviated description of the state of knowledge:</strong> </span></p><p dir="ltr">The development and progression of immunotherapy in recent years has resulted in the approval of five immunotherapy pathways targeting PD-1 (pembrolizumab and durvalumab) or PD-L1 (atezolizumab, nivolumab and avelumab) in patients with progression during or after cisplatin based chemotherapy. The latest updates show that in some types of cancer, positive PD-L1 expression has an effect on treatment effect and qualification. These therapies are used, among others in melanoma, lymphomas, kidney cancer or breast cancer. PD-1 is also used to treat autoimmune and infectious diseases.</p><p dir="ltr"><strong>Conclusions:</strong><span> </span></p><p dir="ltr">Understanding the mechanism of the PD-1/PD-L1 pathway allows to design targeted therapy for individuals. It has been already used in NSCLC treatment program, whether bladder cancer or melanoma. Immunotherapy increases the survival time of patients with advanced stages of cancer. The therapies targeting the PD-1/PD-L1 pathway in autoimmune and infectious diseases are in clinical trials.</p> |
| first_indexed | 2024-12-19T23:00:13Z |
| format | Article |
| id | doaj.art-ab0cfbd22ca340179e734f3c4bc82c52 |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-12-19T23:00:13Z |
| publishDate | 2020-04-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-ab0cfbd22ca340179e734f3c4bc82c522022-12-21T20:02:31ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062020-04-0110411312410.12775/JEHS.2020.10.04.01324308The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseasesDominika Katarzyna Madras0Agata Agnieszka Rocka1Klaudia Daria Szumna2Patryk Piotr Jasielski3Faustyna Piędel4Medical University of Lublin. Faculty of MedicineMedical University of Lublin. Faculty of MedicineMedical University of Lublin. Faculty of MedicineMedical University of Lublin. Faculty of MedicineMedical University of Lublin. Faculty of Medicine<p dir="ltr"><strong>Introduction: </strong></p><p dir="ltr"><strong></strong>PD-1 is programmed death receptor 1 belonging to the CD28 family of receptors. Immune cells have this receptor on their surface. PD-L1 allows cancer cells to avoid the host's response. Connection to the PD-1 receptor leads to the death of the immune cell.</p><p dir="ltr"><span><strong>Objective:</strong> </span></p><p dir="ltr">The use of PD-1 receptors in the treatment of oncological, autoimmune and infectious diseases.</p><p dir="ltr"><span><strong>Abbreviated description of the state of knowledge:</strong> </span></p><p dir="ltr">The development and progression of immunotherapy in recent years has resulted in the approval of five immunotherapy pathways targeting PD-1 (pembrolizumab and durvalumab) or PD-L1 (atezolizumab, nivolumab and avelumab) in patients with progression during or after cisplatin based chemotherapy. The latest updates show that in some types of cancer, positive PD-L1 expression has an effect on treatment effect and qualification. These therapies are used, among others in melanoma, lymphomas, kidney cancer or breast cancer. PD-1 is also used to treat autoimmune and infectious diseases.</p><p dir="ltr"><strong>Conclusions:</strong><span> </span></p><p dir="ltr">Understanding the mechanism of the PD-1/PD-L1 pathway allows to design targeted therapy for individuals. It has been already used in NSCLC treatment program, whether bladder cancer or melanoma. Immunotherapy increases the survival time of patients with advanced stages of cancer. The therapies targeting the PD-1/PD-L1 pathway in autoimmune and infectious diseases are in clinical trials.</p>https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/29711programmed death receptor-1 (pd-1)programmed death receptor ligand-1 (pd-l1)immunotherapyoncologyautoimmunologyinfectious diseases |
| spellingShingle | Dominika Katarzyna Madras Agata Agnieszka Rocka Klaudia Daria Szumna Patryk Piotr Jasielski Faustyna Piędel The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases Journal of Education, Health and Sport programmed death receptor-1 (pd-1) programmed death receptor ligand-1 (pd-l1) immunotherapy oncology autoimmunology infectious diseases |
| title | The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases |
| title_full | The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases |
| title_fullStr | The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases |
| title_full_unstemmed | The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases |
| title_short | The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases |
| title_sort | use of the pd 1 pd l1 pathway as an immunotherapy in oncological diseases autoimmune diseases and infectious diseases |
| topic | programmed death receptor-1 (pd-1) programmed death receptor ligand-1 (pd-l1) immunotherapy oncology autoimmunology infectious diseases |
| url | https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/29711 |
| work_keys_str_mv | AT dominikakatarzynamadras theuseofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT agataagnieszkarocka theuseofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT klaudiadariaszumna theuseofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT patrykpiotrjasielski theuseofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT faustynapiedel theuseofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT dominikakatarzynamadras useofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT agataagnieszkarocka useofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT klaudiadariaszumna useofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT patrykpiotrjasielski useofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases AT faustynapiedel useofthepd1pdl1pathwayasanimmunotherapyinoncologicaldiseasesautoimmunediseasesandinfectiousdiseases |